Browse the evidence

Statin therapy is safe and effective for cardiovascular risk reduction in patients with MASLD and MASH, and elevated transaminases should not prevent prescription.

If you have fatty liver disease (MASLD/MASH), do not avoid statins due to fear of liver damage. Statins are safe, effective for heart health, and may even improve liver markers. Consult your doctor for appropriate intensity based on your overall cardiovascular risk.

Once-weekly semaglutide (2.4 mg) significantly improves health-related quality of life and reduces body weight in obese patients with HFpEF.

If you are obese and have HFpEF, ask your doctor about semaglutide (Ozempic/Wegovy). The STEP-HFpEF trial showed that taking 2.4 mg once weekly significantly improved quality of life and reduced body weight by over 13% compared to placebo.

Dual or triple agonists targeting GLP-1, GIP, and/or Glucagon receptors (GCGR) produce superior weight loss compared to selective GLP-1 receptor agonists alone.

Newer obesity medications that target multiple receptors (like GLP-1, GIP, and Glucagon) are more effective for weight loss than older single-target drugs. These include Tirzepatide and Retatrutide, which are approved or in advanced trials for obesity and diabetes.

Next-generation incretin-based therapies (GLP-1 RAs like semaglutide and dual GLP-1/GIP agonists like tirzepatide) significantly reduce blood pressure and improve cardiovascular outcomes in patients with hypertension, obesity, or type 2 diabetes, acting through both weight loss and direct tissue effects on the cardiovascular system.

If you have high blood pressure, obesity, or type 2 diabetes, ask your doctor about GLP-1 or GLP-1/GIP medications like semaglutide or tirzepatide. These weekly injections not only help with weight loss but also directly lower blood pressure and protect your heart, often allowing you to reduce or stop other blood pressure medications. The benefits extend beyond weight loss through direct effects on your blood vessels and nervous system.

Testosterone therapy preserves lean mass and reduces fat mass when used as an adjunct to incretin-based weight loss medications, potentially counteracting sarcopenia.

Current evidence does not yet support using testosterone to offset muscle loss from GLP-1 weight loss drugs. Resistance exercise and adequate protein intake are the recommended strategies to preserve muscle mass during weight loss.

Semaglutide promotes resolution of non-alcoholic steatohepatitis (NASH) without worsening liver fibrosis in patients with NASH and liver fibrosis.

If you have NASH, ask your doctor about Semaglutide. In clinical trials, the highest dose (0.4 mg daily) helped nearly 60% of patients resolve their liver disease without making scarring worse. It is a promising treatment for liver health.

Genetically modeled GLP-1 and GIP receptor agonism reduces the risk of Non-Alcoholic Fatty Liver Disease (NAFLD) and lowers ALT levels.

Genetic evidence suggests that activating GLP-1 and GIP receptors improves liver health by reducing the risk of NAFLD and lowering ALT levels. This benefit is independent of alcohol consumption, suggesting a direct metabolic effect on the liver.

Mono- and multireceptor agonists combining proglucagon-derived peptides enhance efficacy in managing obesity, diabetes, and conditions affecting the kidneys, liver, and heart.

New combination therapies that target multiple receptors (e.g., GLP-1/GIP, GLP-1/Glucagon) are showing enhanced efficacy for managing obesity, diabetes, and cardiometabolic conditions. Discuss these advanced options with your healthcare provider if standard treatments are insufficient.

A 1.5-year combined lifestyle intervention (normocaloric diet, exercise, CBT) inducing modest weight loss (~5%) normalizes long-term adiposity hormones (leptin, insulin, adiponectin) without triggering orexigenic short-term appetite signals, thereby avoiding the hormonal drive for weight regain typically seen with severe caloric restriction.

To maintain weight loss without triggering intense hunger, focus on a sustainable, healthy diet rather than severe calorie restriction. Combine this with regular mixed exercise (aerobic and resistance) and behavioral strategies (like CBT) over a long period (1.5 years). This approach normalizes metabolic hormones without activating strong hunger signals, making long-term maintenance more feasible than with crash diets.

A novel rice-based diabetes-specific formula (MFDM) containing physically modified rice flour, fructose, and isomaltulose significantly reduces postprandial glucose and insulin responses compared to a standard non-diabetes formula in adults with prediabetes or early type 2 diabetes, while eliciting similar hormonal (GLP-1, GIP, PYY, ghrelin) and satiety responses to a commercial diabetes-specific formula.

For individuals with prediabetes or early type 2 diabetes, consuming a meal replacement or formula containing physically modified rice flour, fructose, and isomaltulose (like the MFDM studied) can significantly blunt postprandial blood sugar and insulin spikes compared to standard non-diabetic formulas. This effect is comparable to established commercial diabetes-specific formulas, making it a viable, potentially more accessible option for managing post-meal glucose levels.

Incretin-based pharmacotherapies (GLP-1, GIP, and triple agonists) significantly improve metabolic dysfunction-associated steatohepatitis (MASH) resolution and fibrosis regression compared to placebo, primarily through weight loss and insulin sensitization, with some agents showing direct hepatic benefits.

For patients with MASH, incretin-based therapies like Semaglutide (2.4mg weekly) are highly effective at resolving liver inflammation and improving fibrosis, often outperforming placebo in clinical trials. While gastrointestinal side effects are common, they can be managed with careful dosing and dietary adjustments, making these drugs a viable and potent option for those who struggle with lifestyle changes alone.

GLP-1 receptor agonists (specifically liraglutide and semaglutide) significantly improve histological features of NASH (steatohepatitis resolution) and reduce liver fat content in patients with Type 2 Diabetes, though they may not consistently improve fibrosis.

If you have Type 2 Diabetes and fatty liver, current guidelines prioritize GLP-1 agonists (like liraglutide or semaglutide) or SGLT2 inhibitors over older drugs like metformin for liver health. These medications not only lower blood sugar but actively reduce liver fat and inflammation. The most effective approach combines these medications with lifestyle changes: aim for 7-10% weight loss through a Mediterranean-style diet and regular aerobic exercise. This combination offers the best chance for resolving NASH and protecting your heart and kidneys.

Pioglitazone (a PPAR-gamma agonist) significantly improves liver inflammation and steatosis in NASH patients, including those with Type 2 Diabetes, but is limited by side effects like weight gain and heart failure risk.

Pioglitazone is an effective, low-cost option for improving liver inflammation in diabetic patients with NASH. However, it is not a first-line choice for everyone due to side effects like weight gain, bone loss, and potential heart failure exacerbation. It is best considered for patients who do not have heart failure or osteoporosis, and who are monitored closely by their doctor.

SGLT2 inhibitors (specifically empagliflozin and dapagliflozin) reduce liver fat content and may improve fibrosis markers in patients with Type 2 Diabetes, offering a cardioprotective and renoprotective alternative to GLP-1 agonists.

SGLT2 inhibitors (like empagliflozin or dapagliflozin) are effective for reducing liver fat and fibrosis in diabetic patients. They are particularly recommended for patients who also have heart failure or kidney disease, as these drugs offer significant protective benefits for these organs. They are a viable alternative to GLP-1 agonists, especially if injections are not preferred.

Tirzepatide provides clinically meaningful HbA1c reduction and dose-proportional weight loss in older adults (≥65 years) with type 2 diabetes who do not have obesity (BMI < 30 kg/m2), without increasing hypoglycemic risk compared to the general population.

If you are over 65 and have type 2 diabetes but are not obese (BMI under 30), tirzepatide is a viable treatment option. It effectively lowers blood sugar and promotes weight loss without increasing the risk of dangerous low blood sugar, provided you are not already on insulin or sulfonylureas. Be aware that gastrointestinal side effects are common, but generally mild, and discontinuation rates due to side effects are slightly higher in this group than in the general population.

GLP-1 receptor agonists (GLP-1RAs) such as semaglutide and liraglutide facilitate weight loss and glycemic control by delaying gastric emptying, stimulating insulin release, and suppressing glucagon secretion.

If you have obesity and struggle to maintain weight loss through diet and exercise alone, GLP-1 medications like liraglutide or semaglutide are FDA-approved options. They work by mimicking a hormone that regulates appetite and digestion. You will need to commit to lifestyle changes alongside the medication, as the drugs are adjuncts, not replacements. Be prepared for potential gastrointestinal side effects, which are common but often subside.

Early and intensive glycemic control, particularly within the first two years of diagnosis, is associated with a lower risk of long-term diabetes-related complications and can lead to diabetes remission in some patients.

If you are newly diagnosed with type 2 diabetes, starting treatment early is crucial. It can help prevent long-term complications and even lead to remission in some cases. Don't delay seeking medical advice or starting prescribed therapies.

Competition preparation in physique athletes, characterized by severe energy restriction and intense training, causes significant reductions in IGF-1, IGFBP-3, and testosterone, along with increased cortisol and SHBG, leading to decreased muscle strength and mood disturbances, all of which are reversible upon recovery.

If you are preparing for a physique competition, expect significant drops in IGF-1, testosterone, and strength, along with increased fatigue and mood disturbances. These are normal, adaptive responses to severe energy restriction and intense training. Do not panic about temporary hormonal suppression; they will fully recover during the post-competition refeeding phase. Monitor your energy availability, but understand that some performance and hormonal decline is inevitable during the peak week.

GLP-1 receptor agonists (GLP-1RA) and dual/triple incretin agonists significantly improve metabolic dysfunction-associated steatohepatitis (MASH) resolution without worsening fibrosis in patients with MASLD, primarily through indirect mechanisms involving weight loss, improved insulin sensitivity, and reduced hepatic lipogenesis.

If you have fatty liver disease (MASLD/MASH), especially with type 2 diabetes or obesity, GLP-1 based medications (like semaglutide or tirzepatide) are currently the most promising pharmacological treatment. They work by reducing liver fat, inflammation, and improving insulin sensitivity. While they may cause temporary stomach issues, they significantly increase the chance of resolving liver inflammation (MASH). The goal is to stop liver damage progression; fibrosis reversal is still being studied in larger trials. Consult a hepatologist or diabetologist for eligibility.

Long-term stable use of GLP-1 receptor agonists results in attenuated gastric emptying effects (tachyphylaxis) compared to recent initiation, reducing perioperative risk.

If you have been on your GLP-1 shot for months, your body has likely adapted, and your stomach empties more normally than when you first started. This makes surgery safer for you than for someone who just started the drug two weeks ago.

GLP-1 receptor agonists (semaglutide, liraglutide) suppress food intake and induce weight loss by targeting distinct neural pathways in the brainstem (NTS, AP, LC, VTA) and hypothalamus, rather than solely relying on peripheral vagal signaling.

GLP-1 medications like semaglutide work by directly acting on specific areas of the brain (brainstem and hypothalamus) to reduce hunger and food intake, rather than just sending signals from the gut. This central action is key to their effectiveness in treating obesity.

Tirzepatide, a dual GIP and GLP-1 receptor agonist, produces superior weight loss (up to -20.9% at 15mg) compared to placebo and established GLP-1 agonists, though it is not yet fully approved for obesity treatment in all contexts.

Tirzepatide (5-15 mg weekly) is a powerful dual-action drug that can help you lose up to 21% of your body weight. It is more effective than current GLP-1 drugs like semaglutide. However, it may not be fully approved for obesity treatment in your region yet, so discuss with your doctor if it's an option for you.

Older anti-obesity medications (Orlistat, Phentermine/Topiramate, Naltrexone/Bupropion) provide modest weight loss (3-10%) but are limited by side effects and lower efficacy compared to newer GLP-1 based therapies.

Older medications like Orlistat, Phentermine/Topiramate, and Naltrexone/Bupropion can help with weight loss (3-10%), but they are less effective than newer GLP-1 drugs. They also have specific side effects like oily stools (Orlistat) or potential mood/cognitive changes (Topiramate/Bupropion). They remain options if newer drugs are inaccessible or unaffordable.

GIP receptor antagonism, when combined with GLP-1 receptor agonism, produces superior weight loss and glycemic control compared to GLP-1 receptor agonism alone.

Current research indicates that combining a GIP receptor antagonist with a GLP-1 agonist (like the investigational drug AMG133) leads to greater weight loss and better blood sugar control than using a GLP-1 agonist alone. This benefit is seen in clinical trials with sustained effects, though the exact mechanism of the GIP part's contribution to weight loss is not fully understood.